CA2180571A1 - Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents - Google Patents

Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents

Info

Publication number
CA2180571A1
CA2180571A1 CA002180571A CA2180571A CA2180571A1 CA 2180571 A1 CA2180571 A1 CA 2180571A1 CA 002180571 A CA002180571 A CA 002180571A CA 2180571 A CA2180571 A CA 2180571A CA 2180571 A1 CA2180571 A1 CA 2180571A1
Authority
CA
Canada
Prior art keywords
colon cancer
hydroxy
phenylazobenzoic acid
acid derivatives
chemotherapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002180571A
Other languages
French (fr)
Other versions
CA2180571C (en
Inventor
Lorin K. Johnson
Marvin H. Sleisenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Inc
Original Assignee
Salix Pharmaceuticals, Inc.
Lorin K. Johnson
Marvin H. Sleisenger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals, Inc., Lorin K. Johnson, Marvin H. Sleisenger filed Critical Salix Pharmaceuticals, Inc.
Publication of CA2180571A1 publication Critical patent/CA2180571A1/en
Application granted granted Critical
Publication of CA2180571C publication Critical patent/CA2180571C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite or an oxidation product of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite or an oxidation product of an active matabolite thereof.
CA002180571A 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents Expired - Fee Related CA2180571C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/178,578 US5498608A (en) 1994-01-07 1994-01-07 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US08/178,578 1994-01-27
PCT/US1995/000055 WO1995018622A1 (en) 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents

Publications (2)

Publication Number Publication Date
CA2180571A1 true CA2180571A1 (en) 1995-07-13
CA2180571C CA2180571C (en) 2001-03-20

Family

ID=22653104

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002180571A Expired - Fee Related CA2180571C (en) 1994-01-07 1995-01-06 Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents

Country Status (18)

Country Link
US (1) US5498608A (en)
EP (1) EP0738152B1 (en)
JP (4) JPH09510958A (en)
CN (1) CN1140994A (en)
AT (1) ATE308327T1 (en)
AU (1) AU691869B2 (en)
CA (1) CA2180571C (en)
CZ (1) CZ286460B6 (en)
DE (1) DE69534564T2 (en)
DK (1) DK0738152T3 (en)
ES (1) ES2248796T3 (en)
FI (1) FI962735A (en)
HU (1) HUT74512A (en)
NO (1) NO962841L (en)
NZ (1) NZ279062A (en)
RO (1) RO116525B1 (en)
RU (1) RU2161487C2 (en)
WO (1) WO1995018622A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (en) 1997-03-14 1997-03-14 Astra Ab New formulation
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
DE19732903A1 (en) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
EP1105141B1 (en) 1998-08-06 2003-11-05 Wolfgang Stremmel Phosphatidylcholine as a medicament for the protection of mucosa
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US7026318B2 (en) * 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
EP1642885B1 (en) 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
TWI314457B (en) * 2001-03-19 2009-09-11 Shionogi & Co
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP1565187A4 (en) * 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic Methods of treating cancer and related methods
JP2007520495A (en) 2004-02-06 2007-07-26 ボロディー トーマス ユリウス Use of aminosalicylic acid in diarrhea-type irritable bowel syndrome
BRPI0507891A (en) 2004-02-20 2007-07-24 Chiron Corp modulation of inflammatory and metastatic processes
FR2867981B1 (en) 2004-03-24 2008-10-31 Genevrier Sa Lab USE OF MONO-AND DISULFATE CHONDROITINE IN THERAPEUTICS
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
CN1988897B (en) * 2004-05-28 2011-06-29 萨利克斯药物有限公司 Use of balsalazide in preparing medicine for radiation induced enteritis
US7932366B2 (en) * 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
CA2608171C (en) 2005-05-13 2014-02-04 Novartis Ag Use of quinolinone compounds for treating drug resistant cancers
CN102670626A (en) * 2005-08-24 2012-09-19 萨利克斯药品公司 Balsalazide formulations and manufacture and use thereof
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
RU2354384C1 (en) * 2007-12-28 2009-05-10 Михаил Владимирович Кутушов Application of organic dyes as means for treatment of oncological diseases
WO2010030781A2 (en) * 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
BR112012027520A2 (en) 2010-04-26 2015-09-15 Salix Pharmaceuticals Ltd Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
GB2080796B (en) * 1980-07-21 1983-10-12 Biorex Laboratories Ltd 2-hydroxy-5-phenylazobenzoic acid derivatives
NZ212419A (en) * 1984-06-25 1988-08-30 Mucan Diagnostics Pty Ltd In vitro diagnostic test for detecting cancer cells producing mucin antigens
US5162202A (en) * 1989-12-12 1992-11-10 Shamsuddin Abulkalam M Rectal mucus test and kit for detecting cancerous and precancerous conditions
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents

Also Published As

Publication number Publication date
EP0738152B1 (en) 2005-11-02
FI962735A (en) 1996-08-26
ATE308327T1 (en) 2005-11-15
NZ279062A (en) 1999-11-29
CA2180571C (en) 2001-03-20
AU1557595A (en) 1995-08-01
HUT74512A (en) 1997-01-28
NO962841D0 (en) 1996-07-05
NO962841L (en) 1996-08-29
EP0738152A4 (en) 2000-12-13
WO1995018622A1 (en) 1995-07-13
HU9601846D0 (en) 1996-09-30
CZ196796A3 (en) 1996-12-11
JP2006096738A (en) 2006-04-13
AU691869B2 (en) 1998-05-28
US5498608A (en) 1996-03-12
DE69534564D1 (en) 2005-12-08
JP2010235629A (en) 2010-10-21
DK0738152T3 (en) 2006-01-30
JP2005320326A (en) 2005-11-17
DE69534564T2 (en) 2006-07-27
FI962735A0 (en) 1996-07-03
EP0738152A1 (en) 1996-10-23
RU2161487C2 (en) 2001-01-10
JP4601466B2 (en) 2010-12-22
CN1140994A (en) 1997-01-22
JPH09510958A (en) 1997-11-04
CZ286460B6 (en) 2000-04-12
ES2248796T3 (en) 2006-03-16
RO116525B1 (en) 2001-03-30

Similar Documents

Publication Publication Date Title
CA2180571A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
CA2192899A1 (en) Composition containing l-carnitine and hydroxycitric acid
CA2294913A1 (en) Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
WO1994027587A3 (en) Sustained antiepileptic therapy
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
AU6171796A (en) Prodrugs of pharmaceuticals with improved bioavailability
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
WO1997012583A3 (en) Stable compositions containing n-propargyl-1-aminoindan
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
GEP20033027B (en) Use of Substituted Benzopyran Analogs for Treatment of Inflammation
CA2009593A1 (en) Medicament containing dihydrolipoic acid as active substance
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
CA2107669A1 (en) Preparation for treating wounds and hemorrhoides
CA2233315A1 (en) Pharmaceutical compositions containing hydroximic acid derivatives
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
EP1666041A3 (en) Xanthine derivatives for treating neurodegenerative disorders
CA2035951A1 (en) Bilobalide derivatives, their applications and formulations containing them
CA2344053A1 (en) Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
CA2120048A1 (en) Pharmaceutical composition having analgesic activity
CA2219359A1 (en) Hydantoin derivatives as intermediates for pharmaceutical active compounds
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
RU95113437A (en) Trans-2-dimethylamino-1-phenyl-3-cyclohexene-trans-1- carboxylic acid ±-ethyl ester as primary orthophosphate and solid pharmaceutical composition having pain-killing activity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed